Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE-6 Poor Responders: 177Lu-PSMA-617 plus standard of care vs standard of care in de novo metastatic hormone-sensitive prostate cancer
2022-502408-57-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Unicancer. Primary endpoints: Overall survival and Radiographic progression-free survival (rPFS). Planned start Mar 2024; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-502408-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502408-57-00.